Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mylan Inc to acquire Abbott's non-U.S. developed markets specialty and branded generics business


Monday, 14 Jul 2014 06:30am EDT 

Mylan Inc:Has entered into a definitive agreement with Abbott Laboratories whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction.Upon closing, Abbott will receive 105 million shares of the combined company worth about $5.3 billion based on Mylan's closing price of $50.20 on July 11, representing an about 21 pct ownership stake. 

Company Quote

50.43
0.07 +0.14%
4:00pm EDT